Emcure Pharmaceuticals Ltd IPO

Emcure Pharmaceuticals Limited is an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. The company is a research and development driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled it to reach a range of target markets across over 70 countries, with a strong presence in India, Europe and Canada. In India, it is present across acute and chronic therapeutic areas, and its key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics.

Open Demat Account

50years

Emcure Pharmaceuticals Ltd IPO Details

Details

Total Shares OfferedOffer to PublicRetail Max (Shares)Pre Issue Promoters HoldingExchangeIssue size
193.65 L114.29 L67.4 L985.91 LBSE₹ 1952.03 Cr
IPO Open DateClose DateLot SizeMin InvestmentIssue TypeListing Date
03 Jul, 2405 Jul, 2414 ₹ 13,440 Book Building10 Jul, 24

Emcure Pharmaceuticals Ltd IPO Dates

  • 03 Jul 2024

    Opening date

  • 05 Jul 2024

    Closing date

  • 08 Jul 2024

    Basis of
    Allotment

  • 09 Jul 2024

    Initiation of
    Refunds

  • 09 Jul 2024

    Credit of
    Shares

  • 10 Jul 2024

    Listing date

Details

SectorType
SectorPharmaceuticals - Indian - Bulk Drugs & Formln
Sub SectorNA
Issue TypeBook Building

Subscription Status

*Values are in Lakhs

Investor TypeSubscription TimesShares Offered*Shares Bid*
QIB76.53x9628224736891932
NII49.34x2888467142526748
Retail7.36x673975649618982
Employee8.81x108900959728
Total48.02x19365347929997390

Subscription Status

Investor Type

QIB

NII

Retail

Employee

Total

*Values are in Lakhs

Emcure Pharmaceuticals Ltd Financial Status

Income Statement

Balance Sheet

Particulars (in Rs. Crores)FY23FY22FY21
Revenue from operations390.86782.22712.11
EBITDA569.38948.01866.32
PAT160.06446.81420.48
Total Assets2,159.412,141.632,252.79
Share Capital180.85180.85180.85
Total Borrowings1,921.721,933.031,670.38
Operating Activities (Net Cash)338.58612.60574.69
Investing Activities (Net Cash)436.92324.11671.64
Financing Activities (Net Cash)1,921.721,933.031,670.38
Net Cashflow141.0247.88260.73

Particulars (in Rs. Crores)

Revenue from operations

EBITDA

PAT

Total Assets

Share Capital

Total Borrowings

Operating Activities (Net Cash)

Investing Activities (Net Cash)

Financing Activities (Net Cash)

Net Cashflow

About Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited as a private limited company under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated April 16, 1981, issued by the Registrar of Companies, Maharashtra at Bombay. The Company became a deemed public company under section 43A (1A) of the Companies Act, 1956 with effect from July 1, 1993 and the word `Private' was removed from the name of the Company and the certificate of incorporation of the Company was endorsed by the Registrar of Companies, Maharashtra at Bombay to that effect. Subsequently, the Company was converted from a deemed public company into a public company upon amendment of section 43A of the Companies Act, 1956 by the Companies Amendment Act, 2000 and the name of the Company was changed to `Emcure Pharmaceuticals Limited', pursuant to its Shareholders resolution dated August 20, 2001 and a certificate of change of name was issued by the RoC on September 18, 2001.

The global pharmaceutical market is expected to sustain growth at a compound annual growth rate of approximately 5.0% to 5.5% between the calendar years 2023 and 2028, to reach approximately US$1,900 billion (approximately Rs.157 trillion) to US$1,950 billion (approximately Rs.161 trillion) in the calendar year 2028. The Indian domestic formulations segment (consumption) is expected to grow at a CAGR of approximately 8% to 9% between the Financial Years 2024 and 2029, to reach approximately Rs.2.9 trillion to Rs.3.0 trillion in the Financial Year 2029, aided by strong demand from the rising incidence of chronic diseases, increased awareness and access to quality healthcare.

Peer Comparison:

  • Dr Reddy's Laboratories Ltd
  • Cipla Ltd
  • Alkem Laboratories Ltd
  • Torrent Pharmaceuticals Ltd
  • Mankind Pharma Ltd
  • Abbott India Ltd
  • J B Chemicals & Pharmaceuticals Ltd

Emcure Pharmaceuticals Ltd IPO Key Points

Strengths

  • Well-placed to leverage leading position in the domestic market.
  • Demonstrated capabilities of building brands.
  • Large, diversified and fast-growing product portfolio in international markets.
  • Strong R&D capabilities driving differentiated portfolio of products.
  • Extensive and diversified manufacturing capacity.

Risk

  • Any manufacturing or quality control problems may damage its reputation, subject it to regulatory action, and expose it to litigation or other liabilities, which could adversely affect the company reputation, business, financial condition and results of operations.
  • Its failures to comply with applicable quality standards may result in product liability claims, which could adversely affect its business, financial condition, cash flows and results of operations.
  • Its manufacturing and research and development operations are subject to operational risks. Any slowdown or shutdown in its manufacturing or research and development operations could adversely affect its business, financial condition and results of operations.

Strategy

  • Increase its Market Share in the Domestic Market.
  • Continue to Invest in Research & Development and Manufacturing Capabilities to Enhance and Grow our Differentiated Product Portfolio.
  • Deepen and Expand its International Presence with a Focused Go-to-Market Approach.
  • Pursue Strategic Acquisitions, Partnerships and In-Licensing Arrangements.
  • Well-placed to leverage leading position in the domestic market.
  • Demonstrated capabilities of building brands.
  • Large, diversified and fast-growing product portfolio in international markets.
  • Strong R&D capabilities driving differentiated portfolio of products.
  • Extensive and diversified manufacturing capacity.

How To Apply for Emcure Pharmaceuticals Ltd Online?

Step 1:

Log in to the BlinkX stock market app and click ‘IPO’ in the Xplore section.

Step 2:

From the list of open IPOs, select the IPO you want to invest.

Step 3:

Go through the IPO details like lot size, price band, about the company, etc.

Step 4:

Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.

Step 5:

Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.

Get your FAQs right

Emcure Pharmaceuticals Ltd's IPO offers shares for up to ₹ 0.01 L It begins on Jul 3, 2024 and ends on Jul 5, 2024.

The price of Emcure Pharmaceuticals Ltd IPO ranges between ₹960 to ₹1008 per share.

The Emcure Pharmaceuticals Ltd IPO opens on Jul 3, 2024 and closes on Jul 5, 2024.

The allotment for the Emcure Pharmaceuticals Ltd IPO will be finalised on Jul 8, 2024. The shares will be listed on BSE and NSE on Jul 10, 2024.

The minimum lot size for Emcure Pharmaceuticals Ltd IPO is 14 shares, priced between ₹960 to ₹1008 per share.

The GMP (Grey Market Premium) of Emcure Pharmaceuticals Ltd IPO fluctuates based on market demand and sentiment.

To check the allotment status of Emcure Pharmaceuticals Ltd IPO, visit the registrar's website, select the IPO, enter your PAN Card number, Application Number, or DP Client ID, and click 'search.'

The Emcure Pharmaceuticals Ltd IPO is getting listed on the BSE and NSE. Bidding opens on Jul 3, 2024, and closes on Jul 5, 2024. The allotment is finalised on Jul 8, 2024.

To apply for the Emcure Pharmaceuticals Ltd IPO, download the BlinkX app, complete KYC, select the IPO, enter bid details, and submit. Verify UPI payment for shares allotment.